See more : N.C. Housing Public Company Limited (NCH.BK) Income Statement Analysis – Financial Results
Complete financial analysis of Stemtech Corporation (STEK) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Stemtech Corporation, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Citizens Financial Group, Inc. (CFG) Income Statement Analysis – Financial Results
- Heilongjiang Interchina Water Treatment Co.,Ltd. (600187.SS) Income Statement Analysis – Financial Results
- Growens S.p.A. (MSPAF) Income Statement Analysis – Financial Results
- Launch Tech Company Limited (2488.HK) Income Statement Analysis – Financial Results
- Hera S.p.A. (HRASF) Income Statement Analysis – Financial Results
Stemtech Corporation (STEK)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.stemtech.com
About Stemtech Corporation
Stemtech Corporation, a stem cell nutrition company, develops science-based products to help the body maintain healthy stem cell physiology in the Americas, Latin America, and Asia. The company's products enhance and support the work of the body's stem cells by releasing more stem cells, helping to circulate them in the blood, and migrate them into tissues, where they can perform their daily function of renewal for optimal health. It offers its dietary supplement products under the RCM System, stemrelease3, Stemflo MigraStem, DermaStem, DermaStem Lift, OraStem, and D-Fuze brands. The company is based in Miramar, Florida.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.92M | 4.56M | 4.32M | 4.38M | 6.62M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 1.00M | 1.16M | 1.02M | 715.15K | 1.23M | 3.42K | 2.51K | 23.53K | 16.64K | 35.33K | 28.59K |
| Gross Profit | 3.92M | 3.40M | 3.30M | 3.67M | 5.39M | -3.42K | -2.51K | -23.53K | -16.64K | -35.33K | -28.59K |
| Gross Profit Ratio | 79.65% | 74.47% | 76.32% | 83.69% | 81.47% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 13.80K | 0.00 | 0.00 | 750.00 | 936.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 6.44M | 6.84M | 4.75M | 3.43M | 5.36M | 24.82K | 36.49K | 23.53K | 16.64K | 35.33K | 28.59K |
| Selling & Marketing | 504.08K | 1.58M | 1.75M | 1.67M | 2.67M | -3.42K | -2.51K | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 6.94M | 8.42M | 6.51M | 5.10M | 8.03M | 21.40K | 33.98K | 23.53K | 16.64K | 35.33K | 28.59K |
| Other Expenses | 1.19M | 7.93K | -124.01K | -31.47K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 8.14M | 8.42M | 6.51M | 5.10M | 8.20M | 21.40K | 33.98K | 23.53K | 16.64K | 35.33K | 28.59K |
| Cost & Expenses | 9.15M | 9.58M | 7.53M | 5.82M | 9.43M | 24.82K | 36.49K | 23.53K | 16.64K | 70.67K | 57.17K |
| Interest Income | 0.00 | 4.10M | 8.33M | 158.74K | 31.41K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 4.89M | 4.10M | 8.33M | 158.74K | 13.68K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 587.80K | 447.39K | 326.26K | 907.00 | 453.89K | 3.42K | 2.51K | 22.82K | -16.64K | 0.00 | 0.00 |
| EBITDA | 48.85K | -3.99M | 1.55M | -1.00M | -2.18M | -21.40K | -33.98K | -23.53K | -33.28K | -70.67K | -57.17K |
| EBITDA Ratio | 0.99% | -100.19% | -69.61% | -20.68% | -32.97% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -4.22M | -5.02M | -3.21M | -1.43M | -2.64M | -24.82K | -36.49K | -23.53K | -16.64K | -70.67K | -57.17K |
| Operating Income Ratio | -85.84% | -110.18% | -74.29% | -32.66% | -39.82% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -1.21M | -3.51M | -3.90M | -295.92K | -205.85K | -12.45K | -9.85K | -4.87K | -3.20K | 0.00 | 0.00 |
| Income Before Tax | -5.43M | -8.54M | -7.11M | -1.73M | -2.84M | -37.27K | -46.34K | -28.40K | -19.84K | 0.00 | 0.00 |
| Income Before Tax Ratio | -110.37% | -187.24% | -164.56% | -39.41% | -42.93% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 95.62K | 8.17M | -65.00 | 28.64K | 4.00 | 2.00 | -46.34K | 0.00 | 0.00 | 0.00 |
| Net Income | -5.43M | -8.63M | -15.28M | -1.73M | -2.79M | -37.27K | -46.34K | -28.40K | -19.84K | 0.00 | 0.00 |
| Net Income Ratio | -110.34% | -189.34% | -353.69% | -39.40% | -42.18% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.07 | -0.19 | -0.41 | -3.20 | -0.52 | -0.07 | -0.09 | -0.05 | -0.04 | 0.00 | 0.00 |
| EPS Diluted | -0.07 | -0.19 | -0.41 | -3.20 | -0.52 | -0.07 | -0.09 | -0.05 | -0.04 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 83.47M | 44.97M | 37.62M | 540.00K | 5.37M | 540.00K | 540.00K | 540.00K | 540.00K | 10.68M | 9.50M |
| Weighted Avg Shares Out (Dil) | 83.47M | 46.01M | 37.62M | 540.00K | 5.37M | 540.00K | 540.00K | 540.00K | 540.00K | 10.68M | 9.50M |
Stemtech Corporation / Viago and Eevia Health Announce Proposed RTO
NAPLES, FL / ACCESSWIRE / December 5, 2024 / Stemtech Corporation (OTCQB:STEK), a US-based company announced this past Tuesday its planned merger ("Merger") with Seacret Direct, LLC ("VIÁGO") and now announces a proposal for a Reverse Takeover (RTO) of Eevia...
Stemtech Corporation and Seacret Direct / Viago Execute Merger Agreement
NAPLES, FL / ACCESSWIRE / December 4, 2024 / Stemtech Corporation (OTCQB:STEK) is pleased to announce the merger agreement with Seacret Direct / VIÁGO, progressing their plan to establish a global leadership position in defining the future of lifestyle, health...
Stemtech Corporation and Viago Announce Strategic Merger
NAPLES, FL / ACCESSWIRE / November 20, 2024 / Stemtech Corporation (OTCQB:STEK) and Seacret Direct, LLC (doing business as VIÁGO) are pleased to announce they have reached an agreement in principle to merge their businesses. This merger represents a transformative...
Stemtech Corporation Announces Uplist to OTCQB, Maintains Focus on Expansion and Transparency
NAPLES, FL / ACCESSWIRE / September 4, 2024 / ("STEK") Stemtech Corporation, the pioneer and trailblazer in the stem cell nutrition sector, is proud to announce that OTC Markets has approved us to quote as an OTCQB stock, symbolizing a...
Stemtech Expands Into The $303 Billion Pet Health Care Market With Launch Of Stempets(TM)
NAPLES, FL / ACCESSWIRE / August 22, 2024 / Stemtech Corporation (OTCQB;STEK), a leader in the development and distribution of stemceutical™ products for humans offered since 2005, is proud to announce an exciting new product line into the pet health...
STEMTECH CORPORATION Update to Shareholders & Independent Business Partners
NAPLES, FL / ACCESSWIRE / July 18, 2024 / STEMTECH CORPORATION, (OTC Pink:STEK) As CEO of the Company, I want to publicly address the recent issues which delayed our annual "10K" and "10Q" filings with the SEC. These delays were...
Stemtech Corporation on Track for CEO and Chairman's Goal for Growth and Global Expansion
Industry Recognition: Stemtech Ranked Top 5% in Direct Selling by 'Business for Home'" NAPLES, FL / ACCESSWIRE / April 19, 2024 / (OTCQB:STEK) Stemtech Corporation, a leader in innovative health and wellness solutions through stem cells technology, is proud to...
Stemtech Corporation Announces Darryl V. Green to Direct Company Rebranding Project
NAPLES, FL / ACCESSWIRE / April 2, 2024 / Stemtech Corporation (OTCQB:STEK), a leading company in the stem cell nutritional sector, is thrilled to announce Mr. Darryl Green will direct our Rebranding Project, marking a significant milestone in the company's...
Stemtech Surges Ahead: Meeting Global Demand with Innovative Stem Cell Nutraceuticals
Revolutionizing Health and Wellness Through Natural Stem Cell Release NAPLES, FL / ACCESSWIRE / March 7, 2024 / Stemtech (OTCQB:STEK), a leading provider of innovative stem cell-based nutraceuticals, announces its staggering growth in the market, with demand surging. Stemtech's proprietary...
Exclusive Events in Doral Florida and Guadalajara Mexico to Showcase Stemtech Revolutionary Stem Cell Nutritional Products
Unlocking Prosperity: Business Opportunities Await! All Entrepreneurs Invited to Seize the Moment NAPLES, FL / ACCESSWIRE / February 21, 2024 / (OTCQB:STEK) Stemtech Corporation, the pioneering leader in stem cell nutrition for nearly 20 years, is thrilled to invite individuals...
Source: https://incomestatements.info
Category: Stock Reports